Blogs

Latest Blogs

[wd_asp id=2]

Beyond Weight Loss: How Incretins Are Redefining Obesity Drug Development

Incretin therapies are changing obesity treatment. Discover why future obesity drug development will be defined by outcomes beyond weight loss.…

What are Immune Checkpoint Inhibitors?

Diseases, especially cancer, suppress the immune system and compromise the body’s biological mechanisms needed to defend itself from the disease…

Fibrosis and SMAD signalling

During normal physiological wound healing, inflammation, angiogenesis and fibrogenesis are all effectively controlled, so that once sufficient matrix has accumulated…

Lipids as Biomarkers of Brain Disorders

Whilst the role of lipids has been particularly relevant within cardiovascular disease, their abundance in the body and high prevalence…

Synexa raises awareness for Rare Diseases Day

28 February 2022 marks Rare Disease Awareness Day and here at Synexa Life Sciences we are sharing our colours to…

Behind The Wave: The Importance of Post-Market Surveillance and its Pertinence to the COVID-19 Pandemic

The world has become engrossed in the vaccine development process since the world’s researchers began their race to provide a…

The Biomarker Association between Depression and Vascular Disease

Major depressive disorder (MDD) has repeatedly emerged as a confounding or prognostic factor in the development of cardiovascular pathologies and…